Taking Psychedelics Seriously
Journal of Palliative Medicine – January 22, 2018
Source: OpenAlex
Summary
Mounting evidence confirms the safety and benefits of psychedelics, yet regulatory hurdles impede their use as medicine. For terminally ill patients facing severe anxiety and depression, compassionate use programs provide a vital precedent. Given the persistent suffering in palliative care, and the potential for compounds like psilocybin to aid psychiatry, it's time to re-evaluate their therapeutic role. Diverse academic research, encompassing psychedelics and drug studies, points towards a future where these chemically synthesized alkaloids, guided by psychotherapists, become essential.
Abstract
Even with an expanding evidence base confirming safety and benefits, political, regulatory, and industry issues impose challenges to the legitimate use of psychedelics. The federal expanded access program and right-to-try laws in multiple states provide precendents for giving terminally ill patients access to medications that have not yet earned FDA approval. Given the prevalence of persistent suffering and growing acceptance of physician-hastened death as a medical response, it is time to revisit the legitimate therapeutic use of psychedelics.